Form 8-K Sage Therapeutics, Inc. For: Nov 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Sage Therapeutics (SAGE) PT Lowered to $48 at RBC Capital
November 2, 2021 1:54 PM EDTRBC Capital analyst Brian Abrahams lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $48.00 (from $52.00) while maintaining a Sector Perform rating.
Abrahams said changes to the CORAL design should improve POS, but it was not a huge surprise and underscores the uncertainties of Zura's commercial profile.
... More